Miniatura

Fitxers

Machine_Learning_Improves_Risk_Stratification_in.3.pdf (3.48 MB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2022-12-20

Llicència de publicació

cc by (c) Mosquera Orgueira, Adrián et al., 2022
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/193126

Machine Learning Improves Risk Stratification in Myelofibrosis: An Analysis of the Spanish Registry of Myelofibrosis

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1097/HS9.0000000000000818

Resum

Myelofibrosis (MF) is a myeloproliferative neoplasm (MPN) with heterogeneous clinical course. Allogeneic hematopoietic cell transplantation remains the only curative therapy, but its morbidity and mortality require careful candidate selection. Therefore, accurate disease risk prognostication is critical for treatment decision-making. We obtained registry data from patients diagnosed with MF in 60 Spanish institutions (N = 1386). These were randomly divided into a training set (80%) and a test set (20%). A machine learning (ML) technique (random forest) was used to model overall survival (OS) and leukemia-free survival (LFS) in the training set, and the results were validated in the test set. We derived the AIPSS-MF (Artificial Intelligence Prognostic Scoring System for Myelofibrosis) model, which was based on 8 clinical variables at diagnosis and achieved high accuracy in predicting OS (training set c-index, 0.750; test set c-index, 0.744) and LFS (training set c-index, 0.697; test set c-index, 0.703). No improvement was obtained with the inclusion of MPN driver mutations in the model. We were unable to adequately assess the potential benefit of including adverse cytogenetics or high-risk mutations due to the lack of these data in many patients. AIPSS-MF was superior to the IPSS regardless of MF subtype and age range and outperformed the MYSEC-PM in patients with secondary MF. In conclusion, we have developed a prediction model based exclusively on clinical variables that provides individualized prognostic estimates in patients with primary and secondary MF. The use of AIPSS-MF in combination with predictive models that incorporate genetic information may improve disease risk stratification.

Matèries

Mielofibrosi, Aprenentatge automàtic, Pronòstic mèdic

Matèries (anglès)

Myelofibrosis, Machine learning, Prognosis

Citació

Col·leccions

Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)

Citació

MOSQUERA ORGUEIRA, Adrián, PÉREZ ENCINAS, Manuel, HERNÁNDEZ SÁNCHEZ, Alberto, GONZÁLEZ MARTÍNEZ, Teresa, ARELLANO RODRIGO, Eduardo, MARTÍNEZ ELICEGUI, Javier, VILLAVERDE RAMIRO, Ángela, RAYA, José maría, AYALA, Rosa, FERRER MARÍN, Francisca, FOX, María laura, VELEZ, Patricia, MORA, Elvira, XICOY, Blanca, MATA VÁZQUEZ, María isabel, GARCÍA FORTES, María, ANGONA, Anna, CUEVAS, Beatriz, SENÍN, Alicia, RAMÍREZ PAYER, Ángel, RAMÍREZ BAJO, María josé, PÉREZ LÓPEZ, Raúl, GONZÁLEZ DE VILLAMBROSÍA, Sonia, MARTÍNEZ VALVERDE, Clara, GÓMEZ CASARES, María teresa, GARCÍA HERNÁNDEZ, Carmen, GASIOR, Mercedes, BELLOSILLO PARICIO, Beatriz, STEEGMANN, Juan luis, ÁLVAREZ LARRÁN, Alberto, HERNÁNDEZ RIVAS, Jesús maría, HERNÁNDEZ BOLUDA, Juan carlos, The Spanish MPN Group (GEMFIN).. Machine Learning Improves Risk Stratification in Myelofibrosis: An Analysis of the Spanish Registry of Myelofibrosis. _HemaSphere_. 2023. Vol. 7, núm. 1, pàgs. e818. [consulta: 24 de gener de 2026]. ISSN: 2572-924. [Disponible a: https://hdl.handle.net/2445/193126]

Exportar metadades

JSON - METS

Compartir registre